Dermatica hydroquinone face cream: read the proposed formula, not just the ingredient menu

The current melasma page lists hydroquinone 4% among possible active ingredients. It also presents azelaic acid, tretinoin and fluocinolone acetonide, with separate ingredient descriptions. The menu does not establish that all of them are combined in every formula or that a reader will receive hydroquinone at all. Dermatica melasma page

The homepage describes personalized, compounded treatment. An actual prescription needs its own named ingredients and specifications. This is different from the fixed public product record discussed in our Obagi Clear review, and neither type of record decides personal suitability without assessment. Dermatica homepage

Dermatica describes its SmartBase cream as containing hyaluronic acid, ceramides, glycerin and panthenol. Those published ingredients give some context about the vehicle, but they do not establish the complete dispensed formula or guarantee tolerability. A cream base and an active menu still need to be connected to the specific prescription. Published formulation description

A separate retinal serum appears on the same page. Its commercial details do not describe a hydroquinone preparation simply because both products are displayed within a skin-care service. The formula-percentage discussion keeps form, active strength and complete identity from being compressed into a single marketing label.

AAD explains that melasma can resemble other skin conditions. A professional may examine the area closely, use a specialized viewing device or sometimes perform a biopsy to clarify the concern. That matters when deciding what an online assessment can establish and when another form of examination might be needed. AAD assessment guidance

Dermatica’s advertised melasma pathway describes a service scope. It does not diagnose every person who arrives through that page or establish that an unfamiliar mark should be treated as pigmentation. The assessment guide offers questions to take to a professional without classifying a reader’s skin.

The homepage advertises a 28-day trial with a $4.99 prescribing fee. Current pricing lists $29.95 per bottle and $59.90 every two months, with free shipping. The service also describes approximately 56-day delivery. Those are distinct advertised units; they should not be silently converted into a personal treatment period or a guaranteed annual cost. Homepage offer Pricing

Pausing, rescheduling and cancellation are advertised. That does not establish every financial consequence after preparation or dispatch, or guarantee that unused medication is refundable. A complete quote should identify the particular preparation and applicable terms rather than borrow the lowest number from an unrelated retail item.

Dermatica advertises free check-ins, progress tracking and formula adaptations. Its terms identify professional medical services through ZipHealth Provider Group and distinguish them from the platform. Reading those roles is useful, but this review has not observed how quickly a clinical concern is answered or whether an individual case would require an examination. Pricing and service promises Terms

The follow-up guide therefore asks about the clinical message route separately from shipping or payment support. A recurring delivery is not evidence that progress has been reassessed. Nor does a subscription period establish how long a professional intends a particular hydroquinone course to continue.

FDA explains that compounded drugs are not FDA-approved and do not receive its premarket safety, effectiveness and quality review. A combination of familiar active names does not bypass that distinction. The public menu is not enough to declare that Dermatica supplies an approved product or an equivalent formulation. FDA compounding explanation

FDA’s hydroquinone communication names Tri-Luma and its specific short-term facial melasma indication. That approval should not be transferred to another mixture because its ingredient names partly overlap. The regulatory guide preserves this boundary without assigning a provider-specific legal status or suggesting that an ingredient list has verified pharmacy compliance. FDA communication

AAD includes hydroquinone among treatments a dermatologist may consider for melasma and emphasizes an individualized plan. That supports a professional discussion of possible benefit, not an assurance that this service’s exact proposed mixture will achieve a promised result by a particular date. AAD treatment context

FDA also reports rashes, swelling and ochronosis associated with hydroquinone skin-lightening products; these are safety concerns, not provider-comparison incidence data. New or worsening changes should not be interpreted by this publication as a sign of success. The CoreAge review applies the same evidence limits to the promoted offer. A useful outcome here is a clearer professional question, not an automatic prescription decision. FDA safety context